retatrutide trial duration treatment clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Significantly Reduces Visceral Fat – Retatrutide, an investigational triple hormone

What the Data Shows The STEP 1 trial, published in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity to 2.4 mg weekly semaglutide or placebo for 68 weeks (1)

The drug did not kill the follicles

58 For all phase 2a, AEs were mild-moderate and GI-related, with no SAEs related to GSBR-1290

Meanwhile, the FDA is still approving new drugs and indications, and the pharma industry is exploring promising leads on potential treatments for everything from MASH and MACE to sleep apnea and osteoporosis

If you must use an alternative cooling device, verify its temperature range with a thermometer before trusting it with temperature-sensitive medications